Recursion Pharmaceuticals (NASDAQ: RXRX) director reports 10b5-1 share sale
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson reported several share moves on January 5, 2026. He converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock at a stated price of $0, then sold 40,000 Class A shares at $4.25 per share and made a gift of 20,000 Class A shares. After these transactions, he directly held 913,839 shares of Class A Common Stock.
The filing also shows he directly holds 4,663,334 shares of Class B Common Stock, each convertible into one Class A share, and additional Class B holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. Multiple stock options to buy Class A shares remain outstanding with exercise prices ranging from $2.48 to $11.40 and expirations between 2030 and 2035. The conversion, sale, and gift were made under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 60,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 60,000 | $0.00 | -- |
| Sale | Class A Common Stock | 40,000 | $4.25 | $170K |
| Gift | Class A Common Stock | 20,000 | $0.00 | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transaction did RXRX director Christopher Gibson report?
Director Christopher Gibson reported converting 60,000 shares of Class B Common Stock into Class A, selling 40,000 Class A shares at $4.25 per share, and gifting 20,000 Class A shares, all dated January 5, 2026.
What is the significance of Class B Common Stock for Recursion Pharmaceuticals insiders?
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date, giving the holder flexibility over when to convert.
What stock options does Christopher Gibson hold in Recursion Pharmaceuticals (RXRX)?
The Form 4 lists several stock options (rights to buy Class A Common Stock) held directly by Christopher Gibson, with exercise prices including $7.25, $10.09, $8.55, $11.40, and $2.48, and expiration dates ranging from 2030 to 2035. The vesting schedules for these options are described as monthly vesting in one-forty-eighth increments from specified start dates.
How are Christopher Gibson’s indirect RXRX holdings structured?
Indirect holdings of Class B Common Stock are reported as held by LAHWRAN-3 LLC and LAHWRAN-4 LLC, where he is a member and manager, and by the Gibson Family Trust, where he serves as trustee. These entities hold Class B shares that are convertible into Class A shares on a one-for-one basis.